Abstract
Abstract 11905: Dexmedetomidine for Sedation During Epicardial Ablation for Ventricular Tachycardia: A Single-Center Experience
Circulation (New York, N.Y.), Vol.146(Suppl_1), pp.A11905-A11905
11/08/2022
DOI: 10.1161/circ.146.suppl_1.11905
Abstract
Introduction: Epicardial ablation of ventricular tachycardia (VT) is mainly performed under general anesthesia (GA). However, GA lowers blood pressure, may interfere with arrhythmia induction, and the use of muscle relaxants precludes identification of the phrenic nerve. Moreover, an anesthesiologist's is required during GA for the whole procedure, which may not always be possible.
Hypothesis: The aim of there study was to evaluate the feasibility and safety of epicardial VT ablations under conscious sedation using dexmedetomidine.
Methods: Between 2018 and 2022, all patients who underwent epicardial VT ablation under dexmedetomidine infusion were prospectively enrolled. All patients received premedication with paracetamol 1 g (acetaminophen 10 mg/ml) and ketorolac 30 mg. Sedation protocol included an i.v. bolus of midazolam (0.03-0.05 mg/kg) followed by continuous infusion of dexmedetomidine (0.2-0.7 mcg/kg/h). In addition, an i.v. fentanyl bolus (0.7-1.4 mcg/kg) was given for short-term analgesia, followed by a second dose after 30-45 minutes. Sedation-related complications were: hypoxia (S02<90%), severe hypotension (MAP<60 mmHg), and bradycardia (HR <45 b/m).
Results: Seventy-one patients with drug-refractory recurrent VT underwent epicardial or endo-epi ablation under conscious sedation. Standard percutaneous sub-xiphoid access was attempted in all patients. in 2 patients the procedure was switched to GA because of intractable pain during epicardial catheter's manipulation. Data from 69 patients were analyzed. Mean age was 65.4±12.1 years and 66.6% of patients were males. Forty-seven patients (68.1%) had non-ischemic cardiomyopathy, 13 patients (18.9%) had ischemic-cardiomyopathy, and 9 patients (13%) had myocarditis. Procedural-related complications occurred in five patients (7.2%), one transient phrenic nerve palsy, two pericarditis, and two vascular complications. No severe adverse events related to the sedation occurred.
Conclusions: Prompt availability of anesthesia support remains crucial for epicardial VT ablation. Continuous infusion of dexmedetomidine in addition to midazolam and fentanyl seems to be a safe and effective sedation protocol in patients undergoing epicardial VT ablation.
Details
- Title: Subtitle
- Abstract 11905: Dexmedetomidine for Sedation During Epicardial Ablation for Ventricular Tachycardia: A Single-Center Experience
- Creators
- Sergio Conti - ARNAS Civico, Palermo, ItalyFrancesco Sabatino - ARNAS Civico, Palermo, ItalyGiuseppe Sgarito - ARNAS Civico, Palermo, Italy
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.146(Suppl_1), pp.A11905-A11905
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1161/circ.146.suppl_1.11905
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/08/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984822985402771
Metrics
1 Record Views